Biopharmaceutical company Rockwell Medical Inc (NASDAQ:RMTI) reported on Monday the receipt of US FDA approval for the manufacture of its Abbreviated New Drug Application for Calcitriol through its contract manufacturing organisation (CMO).
The company added Calcitriol is its US FDA approved active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis.
Earlier this month, the company received US FDA approval of its Prior Approval Supplement for Calcitriol in order to market and commercialise in the US.
Following the manufacturing update for CMO's approval, the US FDA had provided a target date for a response no later than 19 August 2018. The company will provide additional information regarding its plans for commercial production and sales of Calcitriol in the US as it moves forward.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval